Birdwatch Note
2023-03-17 21:22:35 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Context needed: The puberty blocker Lupron was trialled and approved by FDA for precocious puberty not gender affirmation. Lupron is being used ‘off label’ and there are no long-term studies currently available on the effects of this blocker on fertility and sexual function. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020263s050lbl.pdf
Written by E57C3AA7D1F193219D6BFD2DBD441BE013DA65CE11C44C4A3C68C0C75D1896D2
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1636466102367842304
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1636840477109501952
- noteId - 1636840477109501952
- participantId -
- noteAuthorParticipantId - E57C3AA7D1F193219D6BFD2DBD441BE013DA65CE11C44C4A3C68C0C75D1896D2 Participant Details
- createdAtMillis - 1679088155426
- tweetId - 1636466102367842304
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Context needed: The puberty blocker Lupron was trialled and approved by FDA for precocious puberty not gender affirmation. Lupron is being used ‘off label’ and there are no long-term studies currently available on the effects of this blocker on fertility and sexual function. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020263s050lbl.pdf
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-03-17 21:22:35 UTC (1679088155426) |
1969-12-31 23:59:59 UTC (-1) |
2023-03-19 04:40:19 UTC (1679200819065) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-03-17 17:19:38 -0500 | Rating Details | |
| 2023-03-17 17:15:11 -0500 | Rating Details | |
| 2023-03-17 17:00:28 -0500 | Rating Details | |
| 2023-03-18 16:05:15 -0500 | Rating Details | |
| 2023-03-18 16:02:06 -0500 | Rating Details | |
| 2023-03-18 11:49:22 -0500 | Rating Details | |
| 2023-03-18 00:30:09 -0500 | Rating Details | |
| 2023-03-17 23:41:59 -0500 | Rating Details | |
| 2023-03-17 23:12:00 -0500 | Rating Details | |
| 2023-03-17 22:45:02 -0500 | Rating Details | |
| 2023-03-17 22:34:38 -0500 | Rating Details | |
| 2023-03-17 22:31:21 -0500 | Rating Details | |
| 2023-03-17 22:29:41 -0500 | Rating Details | |
| 2023-03-17 22:23:30 -0500 | Rating Details | |
| 2023-03-17 21:25:33 -0500 | Rating Details | |
| 2023-03-17 20:34:41 -0500 | Rating Details | |
| 2023-03-17 20:33:36 -0500 | Rating Details | |
| 2023-03-17 20:31:56 -0500 | Rating Details | |
| 2023-03-17 20:31:24 -0500 | Rating Details | |
| 2023-03-17 20:11:34 -0500 | Rating Details | |
| 2023-03-17 20:10:55 -0500 | Rating Details | |
| 2023-03-17 20:06:43 -0500 | Rating Details | |
| 2023-03-17 19:42:15 -0500 | Rating Details | |
| 2023-03-19 09:01:28 -0500 | Rating Details | |
| 2023-03-19 04:23:03 -0500 | Rating Details | |
| 2023-03-19 01:53:59 -0500 | Rating Details | |
| 2023-03-19 01:53:59 -0500 | Rating Details | |
| 2023-03-17 20:31:24 -0500 | Rating Details | |
| 2023-03-17 20:06:43 -0500 | Rating Details | |
| 2023-03-18 16:02:06 -0500 | Rating Details | |
| 2023-03-19 09:01:28 -0500 | Rating Details | |
| 2023-03-17 23:12:00 -0500 | Rating Details | |
| 2023-03-17 22:23:30 -0500 | Rating Details | |
| 2023-03-18 00:30:09 -0500 | Rating Details | |
| 2023-03-19 04:23:03 -0500 | Rating Details | |
| 2023-03-17 17:19:38 -0500 | Rating Details | |
| 2023-03-17 20:11:34 -0500 | Rating Details | |
| 2023-03-17 19:42:15 -0500 | Rating Details | |
| 2023-03-17 20:10:55 -0500 | Rating Details | |
| 2023-03-18 16:05:15 -0500 | Rating Details | |
| 2023-03-17 22:31:21 -0500 | Rating Details | |
| 2023-03-18 11:49:22 -0500 | Rating Details | |
| 2023-03-17 20:34:41 -0500 | Rating Details | |
| 2023-03-17 20:33:36 -0500 | Rating Details | |
| 2023-03-17 22:45:02 -0500 | Rating Details | |
| 2023-03-17 20:31:56 -0500 | Rating Details | |
| 2023-03-17 17:00:28 -0500 | Rating Details | |
| 2023-03-17 17:15:11 -0500 | Rating Details | |
| 2023-03-17 22:29:41 -0500 | Rating Details | |
| 2023-03-17 23:41:59 -0500 | Rating Details | |
| 2023-03-17 21:25:33 -0500 | Rating Details | |
| 2023-03-17 22:34:38 -0500 | Rating Details |